Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 12 min ago
Peer-reviewedCC BY-NC-NDEULAR rheumatology open

Challenges in implementing the 2020 EULAR Points to Consider on nonadherence in RMDs.

  • Rosaria Talarico1
  • Federica Di Cianni1
  • Silivia Aguilera2
  • Jeanette Andersen3
  • Peter Böhm4
  • Coralie Bouillot5
  • Ricard Cervera6,7
  • Nathalie Costedoat-Chalumeau8,9
  • Sofia de Sousa Guimaraes Calado10,11
  • Ravzan Dragoi12
  • Emma Dures13,14
  • Farida Fortune15,16
19 more authors
  • Ilaria Galetti17
  • Laure Gossec18,19
  • Eric Hachulla20
  • Agnes Kocher10,11
  • Diana Marinello1
  • Ellen Moholt21
  • Marta Mosca1
  • Cristina Pamfil22
  • Valentin Ritschl23,24
  • Vasco C Romão25
  • Carlo Salvarani26,27
  • Valentina Schmolik23,24
  • Savino Sciascia28
  • Richard West29
  • Christina Wettengl10,11
  • Chris Wincup30
  • Bart J F van den Bemt31,32
  • Loreto Carmona33
  • EULAR Study Group on Adherence to Therapy in RMDs
33 affiliations
  1. 1Rheumatology Unit, Azienda Ospedaliero Universitaria Pisana, University of Pisa, Pisa, Italy.
  2. 2Spanish Association for Antiphospholipid Syndrome (SAF España), Elche, Spain.
  3. 3Lupus Europe, Brussels, Belgium.
  4. 4German League Against Rheumatism, Bonn, Germany.
  5. 5Sjögren Europe, Gland, Switzerland.
  6. 6Department of Autoimmune Diseases, University of Barcelona, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
  7. 7IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases)-VIGO Group, Galicia Sur Health Research Institute, Vigo, Spain.
  8. 8National Referral Centre for Rare Autoimmune and Systemic Diseases, Department of Internal Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP) Centre, Université Paris Cité, Paris, France.
  9. 9Université Paris Cité and Université Sorbonne Paris Nord, Inserm, French National Research Institute for Agriculture, Food and Environment (INRAE), Centre for Research in Epidemiology and Statistics (CRESS), Paris, France.
  10. 10Institute of Nursing Science, University of Basel, Basel, Switzerland.
  11. 11Department of Rheumatology, University Hospital Basel, Switzerland.
  12. 12Physical Medicine, Balneology and Rheumatology, University of Medicine and Pharmacy Victor Babes Timisoara, Timisoara, Romania.
  13. 13School of Health and Social Wellbeing, University of the West of England, Bristol, UK.
  14. 14Academic Rheumatology, Bristol Royal Infirmary, Bristol, UK.
  15. 15Institute of Dentistry, Queen Mary University of London, London, UK.
  16. 16Barts Health National Health Service (NHS) Trust, The London Hospital, London, UK.
  17. 17Federation of European Scleroderma Associations, Wavre, Belgium.
  18. 18Sorbonne Université, French National Institute of Health and Medical Research (INSERM), Institut Pierre Louis d'Epidémiologie et de Santé Publique, Team Pepites, Paris, France.
  19. 19AP-HP, Pitié-Salpêtrière hospital, Rheumatology Department, Paris, France.
  20. 20Service de Médecine Interne, Centre de référence des Maladies Auto-immunes et Auto-inflammatoires Systémiques Rares de l'Adulte du Nord, Méditerranée et Guadeloupe (CeRAINOM), University of Lille, CHU Lille, Nord-Ouest, Lille, France.
  21. 21Center for Treatment of Rheumatic and Musculoskeletal Diseases, Diakonhjemmet Hospital, Oslo, Norway.
  22. 22Deptartment of Rheumatology, Emergency County Teaching Hospital, University of Medicine Iuliu Hatieganu, Cluj-Napoca, Romania.
  23. 23Institute for Outcomes Research, Center for Medical Data Science, Medical University of Vienna, Vienna, Austria.
  24. 24Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Vienna, Austria.
  25. 25Rheumatology Department, Hospital de Santa Maria, Unidade Local de Saúde Santa Maria, Lisbon Academic Medical Center and Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
  26. 26Rheumatology Division, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  27. 27University of Modena and Reggio Emilia, Modena, Italy.
  28. 28Department of Clinical and Biological Sciences, University Center of Excellence on Nephrology, Rheumatology and Rare Diseases, ASL Città Di Torino and University of Turin, Turin, Italy.
  29. 29UK Behcet's Syndrome Society, London, UK.
  30. 30Department of Clinical and Academic Rheumatology, King's College Hospital, London, UK.
  31. 31Pharmacy, Sint Maartenskliniek, Nijmegen, The Netherlands.
  32. 32Department of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands.
  33. 33Instituto de Salud Musculoesquelética, Madrid, Spain.
Read full textPDFDOICite

Abstract

Low or nonadherence to treatment is a widespread challenge in the management of rheumatic and musculoskeletal diseases (RMDs), significantly affecting disease outcomes, quality of life, and healthcare costs. The 2020 European Alliance of Associations for Rheumatology (EULAR) Points to Consider provide a comprehensive framework for the prevention, screening, assessment, and management of nonadherence in RMDs. However, real-world implementation of these recommendations remains limited. The challenge is no longer the lack of recommendations, but their integration into routine rheumatology care. This viewpoint discusses the rationale and evidence supporting implementation of the 2020 EULAR Points to Consider in clinical practice and highlights key priorities for the operationalisation of the recommendations into feasible and sustainable care strategies. Particular emphasis is placed on routine adherence assessment, patient-centred communication, multidisciplinary collaboration, and healthcare professional training as essential components of adherence support in RMD care.

Related

  1. Critical gaps in infectious disease prevention and control: insights from IHR-2005 implementation enablers and challenges at key entry points in Bangladesh
    Goutam Kumar Dutta, Md. Khaledul Hasan, Kazi Istiaque Sanin +9
    BMC Public HealthPeer-reviewedCC BY-NC-ND 4.0Epidemiology & public healthCrossref
  2. Nativity and US Residence Duration and Colorectal Cancer Screening Nonadherence.
    Sebastian O Ekenze, Areesh Mevawalla, Aayan E Kibria +3
    JAMA network openPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMCCrossref
  3. Clinical Implications of the Age Threshold in the 2022 ACR/EULAR Classification Criteria for Takayasu Arteritis: A Real-World Study of Patients Aged over 61 Years
    Jang Woo Ha, Oh Chan Kwon, Yong-Beom Park +1
    Diagnostics (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Fever and Painful Skin Lesions: When to Consider Sweet's Syndrome
    Mariana Marques, Joana Couto, Joana Urbano +3
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Perioperative parameters to consider for enhanced recovery in surgery (ERS) in gynecology (excluding breast surgery)
    Henri Azaïs, Thérèse Simonet, Arthur Foulon +7
    Journal of Gynecology Obstetrics and Human ReproductionPeer-reviewedLicence not stated13 citedSurgery & anaesthesiaHAL

Cite

BibTeXRIS
BibTeX
@article{talarico2026challenges,
  title = {{Challenges in implementing the 2020 EULAR Points to Consider on nonadherence in RMDs.}},
  author = {Rosaria Talarico and Federica Di Cianni and Silivia Aguilera and Jeanette Andersen and Peter Böhm and Coralie Bouillot and Ricard Cervera and Nathalie Costedoat-Chalumeau and Sofia de Sousa Guimaraes Calado and Ravzan Dragoi and Emma Dures and Farida Fortune and Ilaria Galetti and Laure Gossec and Eric Hachulla and Agnes Kocher and Diana Marinello and Ellen Moholt and Marta Mosca and Cristina Pamfil and Valentin Ritschl and Vasco C Romão and Carlo Salvarani and Valentina Schmolik and Savino Sciascia and Richard West and Christina Wettengl and Chris Wincup and Bart J F van den Bemt and Loreto Carmona and EULAR Study Group on Adherence to Therapy in RMDs},
  journal = {EULAR rheumatology open},
  year = {2026},
  month = oct,
  doi = {10.1016/j.ero.2026.100261},
  url = {https://europepmc.org/article/MED/42927138},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Challenges in implementing the 2020 EULAR Points to Consider on nonadherence in RMDs.
AU  - Rosaria Talarico
AU  - Federica Di Cianni
AU  - Silivia Aguilera
AU  - Jeanette Andersen
AU  - Peter Böhm
AU  - Coralie Bouillot
AU  - Ricard Cervera
AU  - Nathalie Costedoat-Chalumeau
AU  - Sofia de Sousa Guimaraes Calado
AU  - Ravzan Dragoi
AU  - Emma Dures
AU  - Farida Fortune
AU  - Ilaria Galetti
AU  - Laure Gossec
AU  - Eric Hachulla
AU  - Agnes Kocher
AU  - Diana Marinello
AU  - Ellen Moholt
AU  - Marta Mosca
AU  - Cristina Pamfil
AU  - Valentin Ritschl
AU  - Vasco C Romão
AU  - Carlo Salvarani
AU  - Valentina Schmolik
AU  - Savino Sciascia
AU  - Richard West
AU  - Christina Wettengl
AU  - Chris Wincup
AU  - Bart J F van den Bemt
AU  - Loreto Carmona
AU  - EULAR Study Group on Adherence to Therapy in RMDs
PY  - 2026
DA  - 2026/10/15
JO  - EULAR rheumatology open
DO  - 10.1016/j.ero.2026.100261
UR  - https://europepmc.org/article/MED/42927138
AB  - Low or nonadherence to treatment is a widespread challenge in the management of rheumatic and musculoskeletal diseases (RMDs), significantly affecting disease outcomes, quality of life, and healthcare costs. The 2020 European Alliance of Associations for Rheumatology (EULAR) Points to Consider provide a comprehensive framework for the prevention, screening, assessment, and management of nonadherence in RMDs. However, real-world implementation of these recommendations remains limited. The challenge is no longer the lack of recommendations, but their integration into routine rheumatology care. This viewpoint discusses the rationale and evidence supporting implementation of the 2020 EULAR Points to Consider in clinical practice and highlights key priorities for the operationalisation of the recommendations into feasible and sustainable care strategies. Particular emphasis is placed on routine adherence assessment, patient-centred communication, multidisciplinary collaboration, and healthcare professional training as essential components of adherence support in RMD care.
SN  - 3050-7081
ER  -